Harmony Biosciences Holdings, Inc. (HRMY)

HRMY Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	332.98	311.66	243.78	234.31	228.63	24.46
Short-Term Investments	39.37	41.8	79.33	0	0	0
Cash & Cash Equivalents	372.35	353.46	323.12	234.31	228.63	24.46
Cash Growth	8.28%	9.39%	37.90%	2.48%	834.83%	-70.72%
Receivables	79.72	74.14	54.74	34.84	22.18	4.26
Inventory	5.86	5.36	4.3	4.43	3.82	1.09
Other Current Assets	21.58	18.11	18.13	10.86	8.26	1.7
Total Current Assets	479.5	451.07	400.29	284.44	262.89	31.5
Property, Plant & Equipment	0.21	0.37	0.57	0.82	0.94	1.33
Long-Term Investments	81.51	72.44	23.32	0.75	0.75	0.75
Goodwill and Intangibles	131.15	137.11	160.95	143.92	162.34	72.19
Other Long-Term Assets	154.61	150.46	88.74	3.52	0.15	0.94
Total Long-Term Assets	367.48	360.38	273.59	149	164.18	75.21
Total Assets	846.99	811.45	673.87	433.44	427.07	106.7
Accounts Payable	15.14	17.73	3.79	1	2.56	6.36
Current Debt	15	15	2	2	0	0
Other Current Liabilities	124.11	131.05	73.1	50.77	131.98	13.53
Total Current Liabilities	154.25	163.78	78.88	53.78	134.54	19.89
Long-Term Debt	175	178.57	189.65	189.98	194.25	97.95
Other Long-Term Liabilities	2.34	2.11	2.5	3.18	1.11	0.45
Total Long-Term Liabilities	177.34	180.68	192.15	193.16	195.36	98.4
Total Liabilities	331.59	344.46	271.03	246.94	329.89	118.29
Total Debt	190	193.57	191.65	191.98	194.25	97.95
Debt Growth	-0.82%	1.00%	-0.18%	-1.17%	98.32%	-
Retained Earnings	-104.94	-143.28	-272.13	-453.6	-488.2	-422.86
Comprehensive Income	-0.17	0	-0.15	0	0	0
Shareholders' Equity	515.39	466.99	402.84	186.51	97.18	-422.86
Net Cash / Debt	182.35	159.89	131.47	42.33	34.38	-73.49
Net Cash / Debt Growth	19.72%	21.62%	210.62%	23.11%	-	-
Net Cash Per Share	3.17	2.65	2.15	0.71	1.33	-9.45
Working Capital	325.25	287.29	321.4	230.66	128.35	11.61
Book Value Per Share	9.08	7.85	6.81	3.24	3.77	-54.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).